HK1200358A1 - Plant steroids and uses thereof - Google Patents

Plant steroids and uses thereof Download PDF

Info

Publication number
HK1200358A1
HK1200358A1 HK15101045.6A HK15101045A HK1200358A1 HK 1200358 A1 HK1200358 A1 HK 1200358A1 HK 15101045 A HK15101045 A HK 15101045A HK 1200358 A1 HK1200358 A1 HK 1200358A1
Authority
HK
Hong Kong
Prior art keywords
drug
inhibitor
drug conjugate
agonist
compound
Prior art date
Application number
HK15101045.6A
Other languages
English (en)
Chinese (zh)
Inventor
Michael Davidson
John F. ARNETT
Sadik Elshani
Roelof Rongen
Original Assignee
戴维森洛佩兹有限责任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 戴维森洛佩兹有限责任公司 filed Critical 戴维森洛佩兹有限责任公司
Publication of HK1200358A1 publication Critical patent/HK1200358A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15101045.6A 2011-09-16 2012-09-14 Plant steroids and uses thereof HK1200358A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161535661P 2011-09-16 2011-09-16
US61/535,661 2011-09-16
US201261675966P 2012-07-26 2012-07-26
US61/675,966 2012-07-26
PCT/US2012/055549 WO2013040441A1 (en) 2011-09-16 2012-09-14 Plant steroids and uses thereof

Publications (1)

Publication Number Publication Date
HK1200358A1 true HK1200358A1 (en) 2015-08-07

Family

ID=47883793

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15101045.6A HK1200358A1 (en) 2011-09-16 2012-09-14 Plant steroids and uses thereof

Country Status (16)

Country Link
US (2) US10086082B2 (enExample)
EP (1) EP2755660B1 (enExample)
JP (2) JP6035338B2 (enExample)
KR (1) KR20140093661A (enExample)
CN (2) CN109384825A (enExample)
AU (1) AU2012308332A1 (enExample)
BR (1) BR112014006222A2 (enExample)
CA (1) CA2848979C (enExample)
EA (1) EA201490637A1 (enExample)
HK (1) HK1200358A1 (enExample)
IL (1) IL231541A0 (enExample)
IN (1) IN2014CN02688A (enExample)
MX (1) MX2014003260A (enExample)
PH (1) PH12014500596A1 (enExample)
SG (1) SG11201400652UA (enExample)
WO (1) WO2013040441A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2964269A1 (en) 2013-03-08 2016-01-13 Allergan, Inc. Cyclosporine a-steroid conjugates
KR20150126032A (ko) 2013-03-08 2015-11-10 알러간, 인코포레이티드 스테로이드 약물과 직접 결합된 항생제 컨쥬게이트
US10077268B2 (en) 2014-03-13 2018-09-18 Salk Institute For Biological Studies FXR agonists and methods for making and using
US10301268B2 (en) 2014-03-13 2019-05-28 The Salk Institute For Biological Studies Analogs of fexaramine and methods of making and using
EP3166613A4 (en) 2014-07-09 2018-02-21 Duke University Compositions and methods for the repair of myelin
WO2018132676A1 (en) * 2017-01-13 2018-07-19 Duke University Compositions and methods for the treatment of myelin related and inflammation related diseases or disorders
KR102139678B1 (ko) * 2017-11-24 2020-07-31 전북대학교 산학협력단 N-아세틸 또는 n-아실 아미노산을 포함하는 아토피 또는 가려움증 치료용 조성물
CN110051674A (zh) * 2018-07-26 2019-07-26 中国人民解放军空军军医大学第一附属医院 豆甾醇在制备治疗胃癌的药物中的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000052029A1 (en) 1999-03-04 2000-09-08 Eugene Science Inc. Water-soluble sterol derivative for inhibiting cholesterol absorption and process for preparing the same
WO2001000653A1 (en) * 1999-06-23 2001-01-04 Forbes Medi-Tech Inc. Conjugates of phytosterol or phytostanol with ascorbic acid and use thereof in treating or preventing cardiovascular disease
WO2002072035A2 (en) * 2001-03-14 2002-09-19 Lipogenics, Inc. Novel anti-inflammatory compositions and methods of use
WO2002089820A1 (en) * 2001-05-09 2002-11-14 Mediplex Corporation Formulation of amphiphilic heparin derivatives for enhancing mucosal absorption
SE0103765D0 (sv) * 2001-11-09 2001-11-09 Astrazeneca Ab New use
US20040236125A1 (en) * 2002-09-25 2004-11-25 Forbes Medi-Tech Inc. Novel structures and compositions comprising sterols and/or stanols and specific classes of anti-inflammatory agents and use thereof in treating or preventing cardiovascular disease, its underlying conditions including hyperlipidemia and other disorders having inflammation as part of their aetiology or presentation
WO2004095926A2 (en) 2003-04-28 2004-11-11 Monsanto Technology, Llc Treatment of plants and plant propagation materials with an antioxidant to improve plant health and/or yield
US20050234025A1 (en) * 2004-04-20 2005-10-20 Forbes Medi-Tech Inc. Compositions comprising one or more policosanols and/or policosanoic acids combined with sterol and/or steroid based ascorbic acid derivatives, and uses thereof
JP2008533157A (ja) * 2005-03-14 2008-08-21 マサチューセッツ・インスティテュート・オブ・テクノロジー 疾患および障害の診断および処置のためのナノセル
US8252755B2 (en) * 2006-09-22 2012-08-28 Dharmacon, Inc. Duplex oligonucleotide complexes and methods for gene silencing by RNA interference
CA2669355C (en) * 2006-11-06 2012-10-30 Jina Pharmaceuticals, Inc. Guggulphospholipid methods and compositions
US8188060B2 (en) * 2008-02-11 2012-05-29 Dharmacon, Inc. Duplex oligonucleotides with enhanced functionality in gene regulation
AU2011223730A1 (en) * 2010-03-02 2012-10-18 Imagenetix, Inc. Compositions comprising myristic acid and uses thereof

Also Published As

Publication number Publication date
JP6035338B2 (ja) 2016-11-30
EP2755660A4 (en) 2015-03-18
US20150141390A1 (en) 2015-05-21
EA201490637A1 (ru) 2014-11-28
AU2012308332A1 (en) 2014-04-10
EP2755660A1 (en) 2014-07-23
CN109384825A (zh) 2019-02-26
BR112014006222A2 (pt) 2017-04-11
IN2014CN02688A (enExample) 2015-07-03
MX2014003260A (es) 2014-09-08
CN103987390A (zh) 2014-08-13
IL231541A0 (en) 2014-04-30
US20190083632A1 (en) 2019-03-21
CA2848979A1 (en) 2013-03-21
EP2755660B1 (en) 2019-11-06
JP2014526515A (ja) 2014-10-06
US10086082B2 (en) 2018-10-02
JP2017019871A (ja) 2017-01-26
CA2848979C (en) 2019-11-05
SG11201400652UA (en) 2014-09-26
KR20140093661A (ko) 2014-07-28
PH12014500596A1 (en) 2014-04-21
WO2013040441A1 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
US20190083632A1 (en) Plant steroids and uses thereof
Crouwel et al. Gut microbiota-driven drug metabolism in inflammatory bowel disease
Cheng et al. Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation
Radwan et al. Targeting cancer using cholesterol conjugates
Park et al. Anti-inflammatory mechanism of compound K in activated microglia and its neuroprotective effect on experimental stroke in mice
CN101522703B (zh) 胆酸派生物及其在制备预防或治疗fxr介导的疾病或状况的药物中的应用
Lal et al. Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen
Whitehouse Anti-inflammatory glucocorticoid drugs: reflections after 60 years
JPH06501962A (ja) アンドロスタン及びプレグナン系列の構成要素によるｇａｂａ受容体のアロステリック修飾のための方法、組成物及び化合物
US20190298673A1 (en) PPAR-gamma ACTIVATORS, HDAC INHIBITORS AND THEIR THERAPEUTICAL USAGES
Yoon et al. Adenosine derivatives from Cordyceps exert antitumor effects against ovarian cancer cells through ENT1-mediated transport, induction of AMPK signaling, and consequent autophagic cell death
WO2006007312A2 (en) Co-administration of dehydroepiandrosterone (dhea) congener with pharmaceutically active agents for treating inflammation
Nan et al. Role of nutrition in patients with coexisting chronic obstructive pulmonary disease and sarcopenia
Ruiz et al. Azo-reductase activated budesodine prodrugs for colon targeting
Lin et al. 18β-Glycyrrhetinic acid derivatives induced mitochondrial-mediated apoptosis through reactive oxygen species-mediated p53 activation in NTUB1 cells
Saxena et al. Cholesterol: A prelate in cell nucleus and its serendipity
JP2008515801A (ja) モルヒネおよびモルヒネ前駆体
El Kihel et al. New lithocholic and chenodeoxycholic piperazinylcarboxamides with antiproliferative and pro-apoptotic effects on human cancer cell lines
Zhang et al. Application of a fluorine strategy in the lead optimization of betulinic acid to the discovery of potent CD73 inhibitors
Won et al. Repression of hepatocyte nuclear factor 4 alpha by AP-1 underlies dyslipidemia associated with retinoic acid
Zaufel et al. Secondary (iso) BAs cooperate with endogenous ligands to activate FXR under physiological and pathological conditions
JP2023526315A (ja) 未成熟終止コドンの阻害剤としてのキナゾリン化合物
Silveira-Dorta et al. Synthesis and antiproliferative activity of glutamic acid-based dipeptides
Pfeifer et al. Synthetic LXR agonist suppresses endogenous cholesterol biosynthesis and efficiently lowers plasma cholesterol
Lv et al. MR2938 relieves DSS-induced colitis in mice through inhibiting NF-κB signaling and improving epithelial barrier